|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
CA2049342A1
(en)
|
1989-03-27 |
1990-09-28 |
Sally Bolmer |
Formulations for stabilizing of igm antibodies
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
PT910382E
(pt)
|
1996-04-26 |
2003-10-31 |
Genaera Corp |
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
CN100462066C
(zh)
|
1997-06-27 |
2009-02-18 |
美国生物科学有限公司 |
药剂的新制剂及其制备和应用方法
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
JP2006506442A
(ja)
|
2002-07-09 |
2006-02-23 |
ポイント セラピューティクス， インコーポレイテッド |
ボロプロリン化合物併用療法
|
|
AU2003273299B2
(en)
|
2002-09-05 |
2010-04-01 |
Medimmune, Llc |
Methods of preventing or treating cell malignancies by administering CD2 antagonists
|
|
DK1545204T3
(en)
|
2002-09-06 |
2016-11-14 |
The Government Of The Us Secretary Dept Of Health And Human Services |
Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
|
|
DK1585548T3
(en)
|
2002-12-09 |
2018-09-03 |
Abraxis Bioscience Llc |
COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
ATE459364T1
(de)
|
2003-10-22 |
2010-03-15 |
Univ Johns Hopkins |
Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
|
|
DK1763356T3
(da)
|
2004-04-22 |
2008-10-13 |
Lilly Co Eli |
Sammensætning der omfatter et survivinantisenseoligonuckleotid og gemcitabin til behandling af cancer
|
|
CN1980699B
(zh)
*
|
2004-05-14 |
2012-03-21 |
阿布拉西斯生物科学公司 |
利用白蛋白-结合蛋白作为靶标的治疗方法
|
|
WO2006031370A2
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1799713B1
(en)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
|
WO2006042146A2
(en)
|
2004-10-07 |
2006-04-20 |
Emory University |
Multifunctional nanoparticles conjugates and their use
|
|
US8735394B2
(en)
*
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
SG166775A1
(en)
|
2005-02-18 |
2010-12-29 |
Abraxis Bioscience Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN101355928B
(zh)
|
2005-04-26 |
2013-05-22 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和方法
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
HUE042678T2
(hu)
|
2005-08-31 |
2019-07-29 |
Abraxis Bioscience Llc |
Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
|
|
US8034765B2
(en)
|
2005-08-31 |
2011-10-11 |
Abraxis Bioscience, Llc |
Compositions and methods for preparation of poorly water soluble drugs with increased stability
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
JP2010506583A
(ja)
|
2006-10-17 |
2010-03-04 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
核酸の増幅及び検出装置
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
*
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
CA2668836A1
(en)
*
|
2006-11-07 |
2008-05-15 |
Dow Agrosciences Llc |
Sprayable, controlled-release, male annihilation technique (mat) formulation and insect control method
|
|
US20110262525A1
(en)
|
2006-12-13 |
2011-10-27 |
Schering Corporation |
Methods of treatment
|
|
CA3201293A1
(en)
|
2007-03-07 |
2008-09-12 |
Abraxis Bioscience, Llc |
Nanoparticle comprising rapamycin and albumin as anticancer agent
|
|
AU2008224929A1
(en)
|
2007-03-14 |
2008-09-18 |
Mayo Foundation For Medical Education And Research |
Treating skin cancer
|
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
US20100287638A1
(en)
|
2007-10-01 |
2010-11-11 |
The Hospital For Sick Children |
Neural tumor stem cells and methods of use thereof
|
|
CA2702637A1
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
BRPI0820298A8
(pt)
|
2007-11-09 |
2018-05-08 |
Affitech Res As |
composições e métodos de anticorpos anti-vegf
|
|
EP2310006A4
(en)
|
2008-07-03 |
2012-04-25 |
Mayo Foundation |
CANCER TREATMENT
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
EP2321408A4
(en)
|
2008-08-04 |
2013-04-17 |
Allocure Inc |
MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
WO2010081173A2
(en)
|
2009-01-12 |
2010-07-15 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
EP2416763A4
(en)
|
2009-04-06 |
2015-05-06 |
Mayo Foundation |
PROCESS AND MATERIALS FOR THE RELEASE OF MOLECULES
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
BRPI1014160A2
(pt)
|
2009-04-10 |
2015-08-25 |
Abraxis Bioscience Llc |
Formulações de nanopartículas e aplicações das mesmas
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
CN102458471A
(zh)
|
2009-05-28 |
2012-05-16 |
葛兰素集团有限公司 |
用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
|
|
US8345535B2
(en)
*
|
2009-07-13 |
2013-01-01 |
Lg Electronics Inc. |
Method and apparatus for generating ranging preamble code in wireless communication system
|
|
WO2011066371A2
(en)
*
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
KR20120101050A
(ko)
|
2009-11-05 |
2012-09-12 |
더 유에이비 리서치 파운데이션 |
기저형 유전자형 암의 치료 방법
|
|
AU2010318323A1
(en)
|
2009-11-13 |
2012-06-28 |
Merck Patent Gmbh |
Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
|
|
US9173961B2
(en)
*
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
|
NZ707377A
(en)
|
2010-06-07 |
2015-09-25 |
Abraxis Bioscience Llc |
Combination therapy methods for treating proliferative diseases
|
|
US9466148B2
(en)
|
2010-09-03 |
2016-10-11 |
Disney Enterprises, Inc. |
Systems and methods to dynamically adjust an image on a display monitor represented in a video feed
|
|
WO2012048223A1
(en)
*
|
2010-10-08 |
2012-04-12 |
Abraxis Bioscience, Llc |
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
|
|
WO2012071561A2
(en)
*
|
2010-11-23 |
2012-05-31 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
|
WO2012088388A2
(en)
|
2010-12-23 |
2012-06-28 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
WO2012154861A2
(en)
|
2011-05-09 |
2012-11-15 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
EP2788377B1
(en)
|
2011-11-09 |
2019-01-23 |
The UAB Research Foundation |
Her3 antibodies and uses thereof
|
|
EP2893003B1
(en)
|
2012-09-04 |
2021-03-31 |
Inven2 AS |
Selective and controlled expansion of educated nk cells
|
|
EP2903610B1
(en)
|
2012-10-01 |
2021-11-03 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
RS59880B1
(sr)
|
2013-09-27 |
2020-03-31 |
Hoffmann La Roche |
Formulacije za anti-pdl1 antitelo
|
|
CA2950926A1
(en)
|
2014-06-13 |
2015-12-17 |
Mayo Foundation For Medical Education And Research |
Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
|
|
WO2015195476A1
(en)
|
2014-06-16 |
2015-12-23 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
ES2763318T3
(es)
|
2014-10-06 |
2020-05-28 |
Mayo Found Medical Education & Res |
Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
KR20170101925A
(ko)
|
2014-12-02 |
2017-09-06 |
셀진 코포레이션 |
병용 요법
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
WO2017031368A1
(en)
|
2015-08-18 |
2017-02-23 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
US11571469B2
(en)
|
2016-01-07 |
2023-02-07 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
|
|
EP3413874A4
(en)
|
2016-02-12 |
2020-01-22 |
Mayo Foundation for Medical Education and Research |
TREATMENTS FOR BLOOD CANCER
|
|
AU2017238119A1
(en)
|
2016-03-21 |
2018-10-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
EP3432928A4
(en)
|
2016-03-21 |
2019-11-20 |
Mayo Foundation for Medical Education and Research |
PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
RU2019105550A
(ru)
|
2016-08-05 |
2020-09-07 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
|
|
MX2019002474A
(es)
|
2016-09-01 |
2019-09-18 |
Mayo Found Medical Education & Res |
Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
|
|
JP2019526579A
(ja)
|
2016-09-01 |
2019-09-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ |
Ｔ細胞癌を標的とする為の方法及び組成物
|
|
WO2018048815A1
(en)
|
2016-09-06 |
2018-03-15 |
Nantibodyfc, Llc |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
RU2019110071A
(ru)
|
2016-09-06 |
2020-10-08 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Способы лечения злокачественных новообразований, экспрессирующих pd-l1
|
|
CN109890422A
(zh)
|
2016-09-06 |
2019-06-14 |
梅约医学教育与研究基金会 |
紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
|
|
CA3080406A1
(en)
|
2016-10-28 |
2018-05-03 |
Nrl Pharma, Inc. |
Lactoferrin/albumin fusion protein and production method thereof
|